Treatment of chronic or relapsing COVID-19 in immunodeficiency.

"Disclosure of potential conflict of interest: T. Simpson has received speakers’ fees from Gilead. S. Jolles reports advisory board, speaker, conference, drug safety monitoring board, and project support from CSL Behring, Shire, Takeda, BioCryst Pharmaceuticals, Swedish Orphan Biovitrum, Biotest, Binding Site, LFB, Octapharma, Grifols, UCB Pharma, Sanofi, Pharming, Weatherden, and Zarodex Therapeutics, Limited, and he is a member of the IPOPI SAFE Taskforce and COVIC19 Trial Group. M. Brown is the UK chief investigator for a Gilead remdesivir trial (GS-US-540-9012), local principal investigator for a Gilead remdesivir trial (GS-US-540-5773/5774), and local coinvestigator for the AstraZeneca PROVENT trial. D. Lowe has received travel and subsistence costs for consultancy work for CSL Behring and fees for roundtable discussion from Merck; in addition, he is chief investigator for the COVID-19 antiviral FLARE trial (NCT04499677), and he holds research grants from LifeArc, the UK Medical Research Council, Blood Cancer UK, Bristol-Myers Squibb and the British Society for Antimicrobial Chemotherapy. The rest of the authors declare that they have no relevant conflicts of interest."